Background
Insulin pump therapy (IPT) improves glucose control in people with Type 1 diabetes (T1D) compared with multiple daily injections (MDI). However, their size, the tethered insulin infusion set, intrusiveness when operating the device, and the need to disconnect during showering limits their acceptance to many who may benefit. The Omnipod DASH® Insulin Management System is a small waterproof tubeless device worn on the upper arm which is wirelessly controlled by a handheld device which may be an acceptable alternative. However, there are no randomised controlled trials focusing on the impact on user perceptions of tubeless insulin pump therapy. This pilot study aims to assess the acceptability and feasibility of patch pump therapy compared with usual care in adults with T1D in Australia.
Methods
A pilot multi-site parallel randomised controlled study will be conducted in sixty-four adults with T1D who are managed on MDI or IPT and self-monitoring with finger-stick blood glucose from four specialist diabetes centres in Victoria, Australia. Following carbohydrate counting education, participants will be randomised to use Omnipod DASH® System (Omnipod group) or continue usual care (Usual care group) for 12 weeks, followed by a 12-week extension phase where all participants will use Omnipod DASH® System. The primary study outcome measures are acceptability which will be assessed by the difference in Diabetes Technology Questionnaire “current” (DTQ-current) score at 12 weeks post-randomisation compared to baseline, and feasibility which will be evaluated through study completion rates. Data on process outcomes, resource outcomes, participant centred outcomes, healthcare professional perceptions and glycaemic outcomes will also be collected.
Discussion
This pilot study will provide insights regarding feasibility of the study design and first data regarding user acceptance of insulin patch pump technology in Australian T1D adults. We anticipate that this study will provide information informing the design of a larger study evaluating the impact of patch pumps on subjective outcomes that are of significance to the person living with T1D.
Trial registration:
Australian New Zealand Clinical Trials Registry
(https://anzctr.org.au/)
ACTRN12621001195842 (8th September 2021)
Protocol Version: V3.3; 17th June 2021. Authors (DNO and KK)
Objectives Differentiating status epilepticus (SE) from prolonged episodes of psychogenic non-epileptic seizures (PNES) is not always straight forward and treatment paradigms are dichotomous with potential for harm from misdiagnosis. This study aims to identify the utility of the neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-monocyte ratio (NMR), monocyte-to-lymphocyte ratio (MLR) and platelet-to-lymphocyte ratio (PLR) in differentiating between SE and PNES. Methods Retrospective case control study in adults presenting to a tertiary hospital between April 2017 and December 2020. SE was defined as per ILAE criteria for time point 1. PNES events needed to meet the same time criterion. Patients were excluded if they had other factors that altered peripheral cell counts. After screening 1052 cases, 69 SE events from 56 patients and 38 prolonged PNES events from 22 patients were analysed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.